Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors

• Published in: Journal of hepato-biliary-pancreatic sciences Vol. 21; no. 4; pp. 288 - 295
• Main Authors: Komori, Yoko, Yada, Kazuhiro, Ohta, Masayuki, Uchida, Hiroki, Iwashita, Yukio, Fukuzawa, Kengo, Kashima, Kenji, Yokoyama, Shigeo, Inomata, Masafumi, Kitano, Seigo
• Format: Journal Article
• Language: English
• Published: Japan Blackwell Publishing Ltd 01.04.2014; Wiley Subscription Services, Inc
• Subjects: Adult; Aged; Aged, 80 and over; Disease Progression; DNA, Neoplasm - genetics; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kinases; Lymphatic system; Magnetic Resonance Imaging; Male; Mammalian target of rapamycin inhibitor; Mammalian target of rapamycin signaling pathway; Metastasis; Middle Aged; Neuroendocrine Tumors - diagnosis; Neuroendocrine Tumors - genetics; Neuroendocrine Tumors - metabolism; Pancreatic Neoplasms - diagnosis; Pancreatic Neoplasms - genetics; Pancreatic Neoplasms - metabolism; Pancreatic neuroendocrine tumors; Prognosis; Retrospective Studies; Signal Transduction; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases - biosynthesis; TOR Serine-Threonine Kinases - genetics; Tumors; Young Adult; Immunohistochemistry; Pancreatic neuroendocrine tumors; Mammalian target of rapamycin signaling pathway; Mammalian target of rapamycin inhibitor
• DOI: 10.1002/jhbp.26
• ISSN: 1868-6974

Background Phosphatidylinositol 3‐kinase/Akt/mammalian target of rapamycin (mTOR) pathway dysregulation has been implicated in the development of various human cancers. However, expression of mTOR cascade components in pancreatic neuroendocrine tumors (PNETs) has not been fully explored. The aim of this study was to assess the expression of mTOR pathway in PNETs using immunohistochemistry. Methods From December 1984 to April 2012, we surgically treated 42 patients with PNETs. We used immunohistochemistry to evaluate expression of mTOR, phosphorylated mTOR (p‐mTOR), p70S6 kinase (S6K), phosphorylated S6 ribosomal protein (p‐S6rp), eukaryotic initiation factor 4E‐binding protein 1 (4E‐BP1), and phosphorylated 4E‐BP1 (p‐4E‐BP1) in the resected specimens. The relation between the expression of these molecules and clinicopathological characteristics was investigated. Results We identified the expression of mTOR (28.6%), p‐mTOR (52.4%), S6K (52.4%), p‐S6rp (40.5%), 4E‐BP1 (81.0%), and p‐4E‐BP1 (26.2%) in PNETs. The expression of mTOR, p‐mTOR, S6K, and p‐S6rp was significantly associated with tumor invasion, proliferation, and an advanced‐stage. Particularly, the expression of p‐mTOR was related to clinically relevant factors such as tumor size, vascular invasion, extrapancreatic invasion, lymph node and/or distant metastasis, mitotic count, and European Neuroendocrine Tumor Society TNM staging as well as the 2004 and 2010 World Health Organization (WHO) classification. In addition, p‐S6rp expression was related to vascular invasion, extrapancreatic invasion, lymph node and distant metastasis, mitotic count, and the 2010 WHO classification. In contrast, no significant relation between 4E‐BP1 activation and clinicopathological factors was observed. The expression of p‐mTOR was strongly correlated with that of p‐S6rp (r = 0.474, P = 0.002). Conclusions Our results suggest that activation of the mTOR/S6K signaling pathway plays a significant role in tumorigenesis and progression of PNET.